| | | DEPARTMENT OF HEALTH AND | | | 0 | Form Approved: MB No. 0910-0053. | FOR FDA USE ONLY | |
|---|----------------------|--|--|------------------------------|-----------------------------------|--|---|--|
| FOOD AND DRUG ADMINISTRATION RADIOACTIVE DRUG RESEARCH COMMITTEE (RDI | | | | | Expira | ation Date: 09/30/2020 | - | |
| | | ORT ON RESEARCH USE OF | · · · · · | | AIEC | F SUBMISSION | | |
| | | MEMBERSHIP SU | | | | | | |
| ΝΟΤ | E: | 21 CFR 361.1 Requires that an ar qualifications of RDRC members a | | | | | | |
| Retu | rn (| COMPLETED form to: Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time to review Department of Health and Human Services Food and Drug Administration | | | | | | |
| C 0 59 | ente ffice 901 | and Drug Administration er for Drug Evaluation and Research e of Drug Evaluation IV -B Ammendale Road ville, MD 20705-1266 | contracted to average 1 hour per tree instructions, search existing data s needed, and complete and review comments regarding this burden e collection of information, includin burden, to the address on the right | the collestimate | gather a ection of or any o | nd maintain the data f information. Send ther aspect of this or reducing this | Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff <i>PRAStaff@fda.hhs.gov</i> ease do NOT send your completed form the PRA Staff email address above. | |
| At | ten | tion: RDRC | | | | | , and a person is not required to respond to, a collection of plays a currently valid OMB control number. | |
| A. G | EN | IERAL INFORMATION | | | | | | |
| 1. RI | R | COMMITTEE NUMBER 2. NAME | OF INSTITUTION | | | | | |
| 3 RI | | | | | | | | |
| | | me | | | c. E-I | mail Address | | |
| | | | | | | | | |
| b. | Ad | dress (Include ZIP code) | | | d. Te | lephone No. (Include Are | a Code) | |
| | | | | | o FA | X No. (Include Area Code | 1 | |
| | | | | | | | , | |
| | | | | | | | | |
| | | UIRED MEMBERS (Names and Q Names must be listed. Qualifications | previously submitted to FD | A ma | y be ir | corporated by referen | ce to the appropriate | |
| | | submission. An individual may not b | | | d spec | ialty. | | |
| | | Name | | | ficatio | na attachad? | o, enter date of most recently | |
| | | Name | | e quan | ncatio | | submitted curriculum vitae | |
| | a. | | | □ Y | es | No | | |
| | b. | | | □ Y | es | □ No | | |
| | C. | | | □ Y | es | 🗌 No | | |
| 2. PE | RS | ON(S) QUALIFIED BY TRAINING AND | EXPERIENCE TO FORMUL | ATE R | RADIO | ACTIVE DRUGS | | |
| | Name | | An | Are qualifications attached? | | | o, enter date of most recently submitted curriculum vitae | |
| | a. | | | Y | es | 🗌 No | | |
| | b. | | | □ Y | es | 🗌 No | | |
| | c. | | | □ Y | es | □ No | | |
| 3. PE | RS | ON(S) WITH SPECIAL COMPETENCE | IN RADIATION SAFETY AN | D RAE | DIATIO | N DOSIMETRY | | |
| | Name | | An | Are qualifications attached? | | | o, enter date of most recently submitted curriculum vitae | |
| | a. | | | □ Y | es | □ No | | |
| | b. | | | <u> </u> | es | □ No | | |
| | c. | | | Y | es | □ No | | |
| | _ | DA 2044 (40/40) | | | | | | |

| C. OTHER VOTING MEMBERS NOT LISTED IN SECTION B. (Na | ames and Disciplines; Specialties) |
|--|------------------------------------|
|--|------------------------------------|

| a. | Name and Discipline | Are qualifications attached? | If No, enter date of most recently submitted curriculum vitae |
|--------------|------------------------------------|------------------------------|--|
| | | 🗌 Yes 🗌 No | |
| b. | | 🗌 Yes 🗌 No | |
| с. | | 🗌 Yes 🗌 No | |
| d. | | 🗌 Yes 🗌 No | |
| e. | | 🗌 Yes 🗌 No | |
| f. | | 🗌 Yes 🗌 No | |
| g. | | 🗌 Yes 🗌 No | |
| h. | | 🗌 Yes 🗌 No | |
| i. | | 🗌 Yes 🗌 No | |
| j | | 🗌 Yes 🗌 No | |
| k. | | 🗌 Yes 🗌 No | |
| | ONSULTANTS (i.e., Pediatrician) (I | | |
| | | | |
| | ARY TOTAL AND CHAIRPERSON | | |
| | | | |
| GNATURE OF F | RDRC CHAIRPERSON | | 3. DATE |
| | | | |
| | | FOR FDA USE ONLY | |

Instructions for Completing Radioactive Drug Research Committee (RDRC) Report on Research Use of Radioactive Drugs -- Membership Summary (Form FDA 2914)

Basic research with radioactive drugs may be conducted without an Investigational New Drug Application (IND) when the research is conducted under a FDA-approved Radioactive Drug Research Committee (RDRC) and other conditions, as specified in the RDRC regulations, are met.

RDRC regulations are contained in Title 21, Code of Federal Regulations, Part 361.1 (21 CFR 361.1) and maybe accessed at the following web address: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR=361.1

Guidance regarding RDRC procedures is available from the FDA Center for Drug Evaluation and Research, Office of Drug Evaluation IV, 5901-B Ammendale Road, Beltsville, MD 20705-1266. Information about the FDA RDRC program is available at the RDRC web site at the following web address: http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Oncology/ucm093322.htm

Access to RDRC reporting Forms (2914 - Membership Summary and 2915 - Study Summary), which can be filled out and saved on your computer, can be obtained through the RDRC web site or from the following FDA Forms website:

http://www.fda.gov/opacom/morechoices/fdaforms/default.html

The following instructions address only the administrative aspects of preparing and submitting Form FDA 2914 (Membership Summary) for the following RDRC submissions:

1. Original Application

An application for FDA approval of a RDRC consists of submission of a cover letter summarizing the content of the submission, a Form FDA 2914 (Membership Summary), a current and dated curriculum vitae for each proposed committee member, and a statement that the RDRC agrees to comply with the requirements under 21 CFR 361.1.

2. Annual Report

The annual report, due on or before January 31 of each year, consists of submission of a cover letter summarizing the content of the submission, a Form FDA 2914 (Membership Summary), and Form FDA 2915 (Study Summary) for each study conducted during the preceding calendar year. A Form FDA 2915 (Study Summary) should be submitted even for studies that did not enroll any subjects in the preceding calendar year but have been previously approved by the RDRC and are still open and ongoing.

3. Membership Changes

Changes in membership and applications for new members must be submitted as soon as, or before, vacancies occur on the committee and consists of submission of Form FDA 2914 (Membership Summary) and a current and dated curriculum vitae for each proposed committee member.

WHERE TO SEND THE SUBMISSION:

Food and Drug Administration Center for Drug Evaluation and Research Office of Drug Evaluation IV 5901-B Ammendale Road Beltsville, MD 20705-1266

ATTN: RDRC

Specific instructions for filling out this report are on the next page.

FILLING OUT FORM FDA 2914

(Titles and numbers, when used, correspond to the item blocks on Form FDA 2914)

Section A. General Information

- 1. **RDRC Committee Number** -- Provide the committee number assigned by FDA when the RDRC was initially approved. Leave blank for original applications.
- 2. **Name of Institution** -- Provide the name of the medical institution to which the RDRC is affiliated. For annual reports and membership changes, if the name of the medical institution is different from that provided in the previous submission, please attach a cover letter specifying the old and new names.

3. RDRC Chairperson

- a. NAME Provide the name of the chairperson of the RDRC.
- b. ADDRESS Provide the address to which written correspondence from FDA should be directed. If this address is a post office box number, a street address must also be provided.
- c. E-MAIL Provide the e-mail address of the RDRC chairperson to which electronic correspondences from FDA should be directed.
- d. TELEPHONE NO Provide the telephone number where the RDRC chairperson is usually available during normal working hours. A telephone number must be provided.
- e. FAX No Provide the FAX number of the RDRC chairperson to which facsimile correspondences from FDA should be directed.

MEMBERSHIP - For original applications, annual reports and membership changes, fill in sections B. through E. referenced below.

Section B. Required Members - Provide the names and qualifications of each required member:

- 1. Physician recognized as a specialist in nuclear medicine
- 2. Person qualified by training and experience to formulate radioactive drugs
- 3. Person with special competence in radiation safety and radiation dosimetry

If there are more than three members in a required speciality, attach a separate sheet.

Attach a current and dated curriculum vitae describing relevant degrees, training, and experience for each required member. If this is an annual report and qualifications have been previously submitted to FDA, provide the date of the most recent previous submission for each listed member.

Section C. Other Voting Members Not Listed in Section B - Provide the names, disciplines, and specialties of other committee members.

Attach a current and dated curriculum vitae for each other voting member. If this is an annual report and qualifications have been previously submitted to FDA, provide the date of the most recent previous submission for each listed member.

Section D. Committee Consultants - Provide the names, disciplines, and specialties of committee consultants. Provide a current and dated CV for each consultant used by the committee during the annual report cycle.

Section E. Non-Voting Members, if any - Provide the names and position titles of non-voting committee members.

Section F. Study Summary Total and Chairperson Signature

- 1. *Number of Study Summaries Submitted in This Report* For annual reports, provide the number of Study Summaries included in the submission. For original applications and membership changes, leave blank.
- 2. Signature of the RDRC Chairperson The RDRC chairperson must sign the form.
- 3. *Date* Indicate the date the form is signed by the RDRC chairperson.